Anatumomab mafenatox

Anatumomab mafenatox is a monoclonal antibody designed for the treatment of cancer. This biopharmaceutical is developed by the pharmaceutical industry to target and destroy cancer cells.

Mechanism of Action

Anatumomab mafenatox works by binding to the antigen known as CD30, which is commonly overexpressed on the surface of certain cancer cells. Once bound, the mafenatox component of the drug is internalized by the cancer cell, where it inhibits protein synthesis and triggers apoptosis, or programmed cell death.

Clinical Trials

Anatumomab mafenatox has undergone various clinical trials to assess its safety and efficacy in treating different types of cancer. These trials are crucial in the drug development process, as they provide the evidence needed for regulatory approval by agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Potential Applications

While anatumomab mafenatox is primarily being developed for the treatment of Hodgkin's lymphoma, it may also have potential applications in other types of cancer that express the CD30 antigen, such as anaplastic large cell lymphoma and cutaneous T-cell lymphoma.

See Also

• Monoclonal antibodies in oncology
• Targeted therapy
• Biopharmaceuticals in oncology

References

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian